A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC)

Expert Opinion on Investigational Drugs,2010, 引用: 65

Critical Reviews in Oncology Hematology,2008, 引用: 43

Clinical Pharmacokinectics,2013, 引用: 149

Clinical Colorectal Cancer,2008, 引用: 7

British Journal of Clinical Pharmacology,2008, 引用: 46

Clinical Lung Cancer,2007, 引用: 2

Onkologie,2007, 引用: 1

Ejso,2007, 引用: 17

Cancer Chemotherapy and Pharmacology,2013, 引用: 54

Journal of Thoracic Oncology,2008, 引用: 48